Prevention of occlusive coronary artery thrombosis by prostacyclin infusion in the dog.
D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000648:ultrastructure; D004285:Dogs; D004558:Electric Stimulation; D004566:Electrodes; D011464:Epoprostenol / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D007263:Infusions, Parenteral; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000627:therapeutic use*; D012394:Rosaniline Dyes / Q000494:pharmacology; D013927:Thrombosis / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D011453:Prostaglandins; D012394:Rosaniline Dyes; D011464:Epoprostenol; C008769:sulfan blue